Prognostic Value of the Systemic Inflammation Response Index in Patients with Adenocarcinoma of the Oesophagogastric Junction: A Propensity Score-Matched Analysis

Table 3

Univariate and multivariate Cox regression analyses for overall survival in patients with adenocarcinoma of oesophagogastric junction (unmatched complete datasets).

Variables	Univariate analysis		Multivariate analysis
	HR (95% CI)	value	HR (95% CI)	value
Sex
Female vs. male	0.96 (0.65-1.42)	0.853	—	—
Age
>60 vs. ≤60	1.00 (0.74-1.36)	0.999	—	—
Grade		0.001		0.610^a
Well	Ref.		Ref.
Moderately	6.00 (1.48-24.29)	0.012	1.94 (0.44-8.57)	0.383^a
Poorly	8.95 (2.18-36.77)	0.002	2.09 (0.46-9.45)	0.339^a
Tumour size
>5 cm vs. ≤5 cm	1.62 (1.19-2.21)	0.002	1.23 (0.90-1.69)	0.199^a
AJCC TNM stage		<0.001		<0.001^a
I	Ref.		Ref.
II	2.31 (1.30-4.11)	0.004	1.79 (0.97-3.28)	0.062
III	6.50 (3.83-11.02)	<0.001	4.58 (2.58-8.15)	0.034
Vascular invasion
Yes vs. no	3.23 (2.16-4.85)	<0.001	1.93 (1.26-2.95)	0.003^a
SIRI
>0.68 vs. ≤0.68	1.90 (1.36-2.64)	<0.001	1.55 (1.10-2.17)	0.011^a
NLR
>1.70 vs. ≤1.70	1.42 (1.03-1.98)	0.035	1.23 (0.89-1.71)	0.218^b
PLR
>96 vs. ≤96	1.66 (1.14-2.43)	0.009	1.25 (0.89-1.67)	0.253^c
MLR
>0.20 vs. ≤0.20	1.82 (1.25-2.65)	0.002	1.43 (0.97-2.09)	0.071^d

AJCC: American Joint Committee on Cancer; SIRI: systemic inflammation response index; PLR: platelet lymphocyte ratio; NLR: neutrophil lymphocyte ratio; MLR: monocyte lymphocyte ratio; HR: hazard ratio; CI: confidence interval; Ref.: reference. ^aThe variables (grade, tumour size, TNM stage, vascular invasion, and SIRI) were tested in a multivariate analysis. ^bThe variables (grade, tumour size, TNM stage, vascular invasion, and NLR) were tested in a multivariate analysis. ^cThe variables (grade, tumour size, TNM stage, vascular invasion, and PLR) were tested in a multivariate analysis. ^dThe variables (grade, tumour size, TNM stage, vascular invasion, and MLR) were tested in a multivariate analysis.